CHICAGO, Aug. 18, 2025 (GLOBE NEWSWIRE) — Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, announced today its financial results for the second quarter and six-month period ended June 30, 2025.
Financial Highlights for the Three and Six Months Ended June 30, 2025
Income Statement
Cosmos Health continued its positive trajectory in Q2 2025, delivering double-digit revenue growth of 11.66% and a 51.60% increase in gross profit. The Company remains on track to meet its profitability targets, driven by strong performance across multiple business units. For the first half of 2025, gross profit rose 53.00% to $3.21 million, with gross margin expanding by 374 basis points. Adjusted profitability also improved, with net loss narrowing, supported by higher-margin revenue growth and reduced cash operating expenses.
- Revenue for Q2 2025 was $14.75 million, an increase of 11.66% from $13.21 million in Q2 2024, and for the first half of 2025 revenue was $28.46 million, up 2.4% from $27.79 million in the prior-year period.
- Gross profit rose 51.60% year-over-year in Q2 2025 to $1.16 million, up from $0.77 million in the prior-year period, and for the first half of 2025 gross profit increased 53.0% to $3.21 million, compared to $2.10 million in the prior-year period.
- Gross margin expanded by 208 basis points to 7.89% in Q2 2025, compared to 5.81% in Q2 2024, and for the first half of 2025 gross margin expanded by 374 basis points to 11.30%, compared to 7.56% in the prior-year period.
- Total operating expenses were $3.81 million in Q2 2025, an increase from $3.27 million in Q2 2024, and for the first half of 2025 total operating expenses were $6.69 million, compared to $6.44 million in the prior-year period.
- Adjusted for non-cash items, cash operating expenses declined in the first half of 2025.
- EBITDA remained stable at ($2.19 million) in Q2 2025, compared to ($2.04 million) in Q2 2024, and for the first half of 2025 EBITDA improved to ($2.59 million), compared to ($3.52 million) in the prior-year period.
- Adjusted EBITDA was essentially unchanged at ($1.31 million) in Q2 2025, compared to ($1.32 million) in Q2 2024, and for the first half of 2025 adjusted EBITDA improved to ($1.14 million), compared to ($1.96 million) in the prior-year period.
- Adjusted net income (loss) was ($1.60 million) in Q2 2025, compared to ($1.56 million) in the prior-year period, and for the first half of 2025 adjusted net loss narrowed to ($1.52 million), compared to ($2.26 million) in the prior-year period.
Balance Sheet
Total assets grew to $61.84 million, supporting an increase in stockholders’ equity to $26.23 million and reinforcing the Company’s strong capital base. The liabilities-to-assets ratio remained at a prudent 57.6%, underscoring continued financial discipline.
- Total assets increased by 13.9% to $61.84 million as of June 30, 2025, up from $54.31 million at year-end 2024, reflecting enhanced liquidity and a diversified asset base supported by a solid real estate and intellectual property portfolio.
- Total liabilities were $35.60 million as of June 30, 2025, compared to $29.78 million at year-end 2024, primarily reflecting the use of credit facilities and financing arrangements to support business growth.
- Total stockholders’ equity increased to $26.23 million from $24.53 million at year-end 2024, reflecting a stronger capital base.
Management Commentary
Greg Siokas, CEO of Cosmos Health, stated: “We are pleased with our Q2 results and the steady progress achieved across multiple strategic areas. The quarter was marked by double-digit revenue growth, a substantial increase in gross profit, and continued gross margin expansion. Our asset base also expanded notably, accompanied by an increase in stockholders’ equity.
Looking ahead, we remain laser-focused on driving efficiencies across the business, which we anticipate will yield tangible results and position us well to achieve cash flow positive status, a key turning point for Cosmos.
Lastly, we are particularly excited about the recently announced financing facility of up to $300 million, which enables us to build a leading portfolio of digital assets while also providing growth capital to accelerate our expansion plans. We have already completed our first purchases of Ethereum and look forward to fully leveraging this facility to position Cosmos as a significant player in the crypto space.”
| UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) | |||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||
| (in $) | |||||||||||
| GAAP – Figures | |||||||||||
| REVENUE | 14,745,702 | 13,206,717 | 28,458,230 | 27,791,190 | |||||||
| GROSS PROFIT | 1,163,814 | 767,248 | 3,213,613 | 2,100,874 | |||||||
| TOTAL OPERATING EXPENSES | (3,809,133 | ) | (3,269,274 | ) | (6,692,077 | ) | (6,439,008 | ) | |||
| GAIN (LOSS) FROM OPERATIONS | (2,645,319 | ) | (2,502,026 | ) | (3,478,464 | ) | (4,338,134 | ) | |||
| NET LOSS | (2,828,068 | ) | (2,590,711 | ) | (3,646,165 | ) | (4,457,401 | ) | |||
| NON-GAAP Figures* | |||||||||||
| ADJUSTED EBITDA | (1,312,280 | ) | |||||||||